Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021
Paratek Pharmaceuticals (Nasdaq: PRTK) will host a conference call and live audio webcast on August 9, 2021, at 4:30 p.m. EDT to discuss its corporate update and financial results for Q2 2021. The call will provide insights into the company’s performance and development activities. Paratek's lead product, NUZYRA (omadacycline), is an antibiotic for community-acquired bacterial pneumonia and skin infections. The company also has a collaboration with Zai Lab for omadacycline in China and is exploring opportunities in treating Nontuberculous Mycobacterial pulmonary disease, a market potentially worth $1 billion in the U.S.
- Paratek's lead product, NUZYRA, shows promise in treating serious infections.
- The company has a collaboration with Zai Lab for commercialization in China, enhancing market reach.
- Potential $1 billion market opportunity for NUZYRA in treating Nontuberculous Mycobacterial pulmonary disease.
- None.
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, August 9, 2021 at 4:30 p.m. EDT to provide a corporate update and report its financial results for the second quarter ended June 30, 2021.
The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.
Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304. The conference ID is 10016029. Investors can also access the call at http://public.viavid.com/index.php?id=146149.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The Company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA. Paratek estimates this opportunity represents a potential
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from BARDA, valued up to
For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.
About NUZYRA®
NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.
Please see full Prescribing Information for NUZYRA at www.NUZYRA.com.
Forward Looking Statements
This press release contains forward-looking statements, including regarding validation of the potential clinical utility of NUZYRA to help address public health emergencies including protecting our civilian and military personnel as a medical countermeasure, including pandemics. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.
For Investors:
Hans Vitzthum
LifeSci Advisors
ir@ParatekPharma.com
Phone: 617-430-7578
For Media:
Beth Kramli
Scient PR
Beth@scientpr.com
Phone: 908-568-9721
FAQ
What is the date of Paratek Pharmaceuticals' upcoming conference call?
What financial results will Paratek Pharmaceuticals report on August 9, 2021?
What is NUZYRA and what conditions does it treat?
Is Paratek Pharmaceuticals involved in any collaborations?
What is the potential market size for NTM Pulmonary Disease treatment in the U.S.?
